MARKET

BMRA

BMRA

Biomerica Inc
NASDAQ
0.6700
-0.0054
-0.79%
Opening 11:06 04/26 EDT
OPEN
0.7000
PREV CLOSE
0.6754
HIGH
0.7000
LOW
0.6613
VOLUME
35.05K
TURNOVER
0
52 WEEK HIGH
2.130
52 WEEK LOW
0.6600
MARKET CAP
11.27M
P/E (TTM)
-1.7683
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BMRA last week (0415-0419)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Soligenix (NASDAQ:SNGX) stock increased by 95.1% to $0.75 during Monday's pre-market session. The company's market cap stands at $7.9 million. Cartesian Therapeutics and Longeveron also moved upwards. Losers Marinus Pharma and PaxMedica stock decreased by more than 20%.
Benzinga · 04/15 12:07
Weekly Report: what happened at BMRA last week (0408-0412)?
Weekly Report · 04/15 12:00
Biomerica Advances IBS Treatment with inFoods Product, Expands Physician Network Nationwide
Biomerica has expanded its reach with adoption by new offices in targeted regions, including the Southeast, Northeast and Midwest. The Company has activated over 30 new physician groups for the inFoods IBS product. The average increase in the number of physicians prescribing in foodys more than doubled each quarter.
Benzinga · 04/15 11:54
BIOMERICA INC: RECEIVES NOTICE OF ALLOWANCE FOR FIVE NEW PATENTS IN EUROPE, CANADA AND JAPAN
Reuters · 04/15 11:47
Biomerica provides update on inFoods® IBS expansion
Barchart · 04/15 06:47
Reported Late Friday, Biomerica Q3 EPS $(0.11) Up From $(0.12) YoY, Sales $1.02M Down From $1.11M YoY
Biomerica reported quarterly losses of $0.11 per share. The company reported $1.02 million in sales this quarter. Biomerica's sales for the quarter were down 8.46 percent from the same period last year. The stock is down 2.8 percent today.
Benzinga · 04/15 06:20
Biomerica GAAP EPS of -$0.11, revenue of $1M
Biomerica reports Q3 GAAP EPS of -$0.11, revenue of $1M (-9.1% Y/Y). The company maintained a cash and equivalents balance of $5.3 million as of February 29, 2024. Biomerica is expected to report fiscal year 2024 results on April 15.
Seeking Alpha · 04/15 04:53
More
About BMRA
Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. It is also engaged in the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. The Company's InFoods IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The Company’s two subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets.

Webull offers Biomerica Inc stock information, including NASDAQ: BMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMRA stock methods without spending real money on the virtual paper trading platform.